Enzalutamide
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ENZALUTAMIDE |
|---|---|
| Type | Drug |
| Aliases | XtandiЕнзалутамід |
| Status | pending_clinical_signoff |
| Diseases | DIS-PROSTATE |
| Sources | SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Drug Facts
| Class | Androgen receptor pathway inhibitor (ARPI) |
|---|---|
| Mechanism | Direct AR antagonist — competes with androgen for binding, blocks AR nuclear translocation, DNA binding, and coactivator recruitment. Active even in low-androgen castrate environment. |
| Typical dosing | 160 mg PO once daily, with or without food. Continue until progression or unacceptable toxicity. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Active in pre-chemotherapy and post-docetaxel mCRPC. CNS penetration > apalutamide / darolutamide; cognitive AEs more common in elderly.
Used By
Contraindications
CI-PROSTATE-SEIZURE-HISTORY-ENZALUTAMIDE- CI-PROSTATE-SEIZURE-HISTORY-ENZALUTAMIDE
Regimens
REG-ADT-ENZALUTAMIDE- ADT + enzalutamide (continuous)